OR WAIT null SECS
December 31, 2024
Article
Cell therapy, particularly CAR-T, is expanding into autoimmune diseases like lupus and multiple sclerosis. While promising, safety, efficacy, and broad applicability remain uncertain.
December 05, 2024
Women who gave birth after infertility without receiving fertility treatments had an elevated risk of developing SARDs, such as lupus.
December 03, 2024
The GLEAM trial is currently enrolling patients to receive SC291, with data expected in 2025.
November 27, 2024
Patients in the anifrolumab arm also had lower rates of damage accrual.
November 25, 2024
Hypovitaminosis D was more prevalent in patients with lupus nephritis compared to patients with systemic lupus erythematosus without kidney disease.
November 24, 2024
Video
Arnold discussed his research in analyzing and improving current classifications of ANA-RMDs and how it could help improve research in the field.
November 21, 2024
Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.
November 19, 2024
The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.
November 16, 2024
Schett discussed findings from 2 early studies of CD19 CAR T-cell therapy.
A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.
